Why Transgenic and Knockout Animal Models should be used (for Drug Efficacy Studies in Cancer)

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Cancer Metastasis Review

• Publication date

  1998-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1023/A:1006196614142PMID 10352883
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Recent animal models of bladder cancer and their application in drug discovery: an update of the literature

  2025cites this paper
• Nonclinical drug development

  2022cites this paper
• The N-butyl-N-4-hydroxybutyl Nitrosamine Mouse Urinary Bladder Cancer Model.

  2018cites this paper
• Urothelial Carcinoma

  2018influential citation
• Inhibition of Gli1 and Gli2 as a targeted therapy for bladder cancer

  2018cites this paper
• Development of a murine intravesical orthotopic human bladder cancer (mio-hBC) model.

  2018cites this paper
• Animal models of colorectal cancer with liver metastasis.

  2017cites this paper
• Animal models of urinary bladder cancer and their application to novel drug discovery

  2014cites this paper
• Non-Clinical Drug Development

  2013cites this paper
• Development of a Clinically-Precise Mouse Model of Rectal Cancer

  2013cites this paper
• Is SPME a destination or just another station for bioanalysis?

  2013cites this paper
• Mighty, But How Useful? The Emerging Role of Genetically Engineered Mice in Cancer Drug Discovery and Development

  2012cites this paper
• Physical Co-registration of Magnetic Resonance Imaging and Ultrasound in vivo

  2012cites this paper
• Human Tumor Xenograft Efficacy Models

  2011cites this paper
• Signal transduction therapy of cancer.

  2010cites this paper
• Cáncer de colon experimental: caracterización del modelo mediante marcadores tumorales y moléculas de adhesión

  2009influential citation
• EVALUATION OF HUMAN PROLACTIN, ITS ANTAGONIST, AND ANTAGONIST-BASED FUSION PROTEINS AS CHEMOPREVENTATIVE AND THERAPEUTIC AGENTS

  2007cites this paper
• Immunological responses can have both pro- and antitumour effects: implications for immunotherapy

  2007cites this paper
• CHAPTER 29 – Preclinical Drug Development

  2007cites this paper
• Targeted cancer therapy: promise and reality.

  2007cites this paper
• Genetically engineered models have advantages over xenografts for preclinical studies.

  2006cites this paper
• PRECLINICAL TESTING AND VALIDATION OF NOVEL ANTICANCER AGENTS

  2006cites this paper
• Mouse models in oncogenesis and cancer therapy

  2006cites this paper
• An orthotopic colon cancer model for studying the B7-H3 antitumor effect in vivo

  2006cites this paper
• TRANSGENIC ANIMAL SCIENCE : PRINCIPLES AND METHODS Transgenic Animals and Genetic Research

  2005cites this paper
• Mouse Models of Colorectal Cancer and Liver Metastases

  2005cites this paper
• Trials, Tribulations, and Trends in Tumor Modeling in Mice

  2004cites this paper
• Tyrosine kinase receptors as attractive targets of cancer therapy.

  2004cites this paper
• Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1254 Application of a New Logic to Old Drugs: Angiogenesis Inhibition in Neuroblastoma

  2003cites this paper
• Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models.

  2003cites this paper
• Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers.

  2003cites this paper
• Human Tumor Xenografts as Predictive Preclinical Models for Anticancer Drug Activity in Humans: Better than Commonly Perceived—But They Can Be Improved

  2003cites this paper
• The use of animal models in cancer research

  2002cites this paper
• Autochthonous mouse models for prostate cancer: past, present and future.

  2001cites this paper
• Murine models for experimental therapy of pediatric solid tumors with poor prognosis

  2001cites this paper
• 2-Methoxyestradiol induces G2/M arrest and apoptosis in prostate cancer.

  2001cites this paper
• Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.

  2000cites this paper
• Tumor angiogenesis: molecular pathology, therapeutic targeting, and imaging.

  2000cites this paper